Wednesday, May 8 2024 | Time 19:50 Hrs(IST)
image
Business EconomyPosted at: Aug 11 2022 8:07PM


Aurobindo Pharma net profit declines 32 pc at Rs 520 cr

Hyderabad, Aug 11 (UNI) Aurobindo Pharma Ltd on Thursday report an 32.4 percent decline in consolidated net profit in Q1 FY23 at Rs 520.5 crore as against Rs 770 crore in the same quarter last fiscal even as the revenue from operations up 9.4 per cent Y-O-Y..
Revenue from Operations stood at Rs 6,235.9 crores during the quarter compared to Rs 5,702 crore in the corresponding period in previous year, Hyderabad-based pharma company said in a release here.
US formulations revenue increased by 10.8 percent YoY to Rs 2,971.1 crore while Europe formulation revenue stood at Rs 1,548.1 crores with decrease of 2.2 percent Y-o-Y mainly due to Euro currency depreciation.
Growth Markets grew by 30.8 percent Y-o-Y to INR 430.6 Cr
Research & Development (R&D) spend at INR 310 crore, 5.0 per cent on revenues (Q1 FY22: 6.3%) Received final approval for 10 ANDAs including 4 injectable products from the USFDA
Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We delivered a good performance amidst a challenging environment. Investments in the product portfolio continued at a healthy pace as reflected in the filings and launches in the quarter. Our focus on the development of specialty products pipeline will establish new avenues to grow the business in future. This along with our aim to drive sustained improvement in profitability through newer avenues will enhance improved profitability over medium to long term.”
Aurobindo, an integrated global pharmaceutical company, develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.
The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC,Brazil ANVISA.
The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
UNI KNR GNK
Please log in to get detailed story.
Tags: #Aurobindo Pharma net profit declines 32 pc at Rs 520 cr
More News

AIC T-Hub selects startups to drive Innovation in the Mobility Sector

08 May 2024 | 7:14 PM

Hyderabad, May 8 (UNI) T-Hub, India's leading startup incubator, in collaboration with Atal Incubation Centre (AIC), on Wednesday announced the launch of the mobility cohort of the AIC T-Hub Program.

see more..

TVS SCS wins new business deal for Eicher’s bus facility in Baggad

08 May 2024 | 6:31 PM

Kolkata, May 8 (UNI) TVS Supply Chain Solutions Limited, a global supply chain solutions provider and one of the largest and fastest-growing integrated supply chain solutions providers in India, has won a new business contract from VE Commercial Vehicles (VECV) for managing their in-plant warehousing and logistics function at their Eicher bus factory located in Baggad, Madhya Pradesh.

see more..

WOW skin science announces revamped products 'Activated Naturals'

08 May 2024 | 6:26 PM

New Delhi, May 8 (UNI) WOW Skin Science, India’s leading premium beauty and wellness brand, announced its revamped products proposition 'Activated Naturals’ here on Wednesday.

see more..
Stock market on roller coaster; BSE Sensex ends 45 points down

Stock market on roller coaster; BSE Sensex ends 45 points down

08 May 2024 | 6:09 PM

Mumbai, May 8 (UNI) The stock market was on a roller coaster on Wednesday as the BSE sensex moved up and down during the day amidst concerns over the outcome of Lok Sabha election.

see more..

08 May 2024 | 5:42 PM

The Company received orders worth Rs 302,812 crore at the group level during the year ended March 31, 2024, registering a robust y-o-y growth of 31 per cent. During the year, orders were received across multiple segments like Onshore & Offshore verticals in Hydrocarbon, Metros, Urban Transit Systems, Airports, Roads & Bridges, Residential, Renewables, Transmission & Distribution and the Precision Engineering sectors.

see more..
image